We invest in the biological cycles that shape human potential: sleep, hormonal, reproductive, and longevity.
Circadian science and sleep as the foundation of recovery, cognition, and long-term health — an underserved frontier of daily performance.
Hormonal monitoring and women's health, a historically overlooked market now driving demand for cycle-aware diagnostics and therapeutics.
Fertility, IVF, and reproductive longevity expanding as people build families later and seek to extend their reproductive window.
Advances in aging biology creating unprecedented demand to extend healthspan, not just lifespan.
Our investments span pharmaceuticals, platforms, devices, and diagnostics.
Four forces are converging to expand demand across every cycle we back.
Wearables and at-home diagnostics make every cycle measurable in real time, and consumers now pay out of pocket to improve sleep, energy, and daily performance — a shift from treating disease to enhancing baseline.
Decades of underinvestment reversing as femtech and hormonal health surge, opening a large, historically ignored market.
Families formed later are driving demand for fertility, IVF, and reproductive-longevity solutions.
An aging population and rapid advances in aging biology are fueling demand to extend healthspan, not just lifespan.
We understand the science. With a physician-scientist and Harvard Medical School faculty member as General Partner, we evaluate opportunities with clinical and research depth that most early-stage firms cannot match.
We help founders build. Beyond capital, we bring hands-on guidance in founding, leading, and scaling startups for exit, drawn from our own operational experience building and advising hundreds of the world's leading organizations. Our portfolio companies don't just get funded. They get the tools, networks, and strategic support to grow.
We find what others miss. AI agents augment our network, helping us identify breakthrough science, evaluate research quality, and map commercial potential at scale. Additionally, our network of scientists and clinicians across 30+ institutions, as well as specialized co-investors, surfaces exceptional founders before they hit the traditional VC radar.
Life sciences is at an inflection point. The molecular systems we once studied only to treat disease can now be measured, tuned, and extended — turning biology from a map of our limits into a toolkit to surpass them.
For the first time, the science, the tools, and the market have arrived together. Our biological cycles are legible in real time, consumers are paying to optimize them, and demographic and scientific tailwinds are compounding into 12–14% annual growth across the sector. There has never been a bigger opportunity for emerging life science companies.
So, what if there was a venture firm that leverages community to find, fund, and support the best life sciences startups from Day 1?
Legacy Venture Capital was founded to answer that question. We invest at pre-seed and seed in the biological cycles that enhance human potential — backing the founders learning to read, tune, and extend them.